0 Development in Pharma R&D Charles Baum, MD, PhD Senior Vice President, Pfizer 1 R&D Productivity http://www.reuters.com/ 2 Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2008;…

…These resources include a high throughput small molecule and RNA interference screening center, imaging and phenotyping facilities, preclinical testing programs, Good Manufacturing Practices (GMP) facilities in the pharmacy and for…

…protections, vulnerable populations, engagement in research, and quality improvement versus research. Dr. Sonne received her pharmacy degree at MUSC. Elyse Summers, JD, is the President and CEO of the Association…

NOVEL AND EXCEPTIONAL TECHNOLOGY AND RESEARCH ADVISORY COMMITTEE Minutes of Meeting December 5-6, 2019 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NExTRAC Meeting…

Preface: A Brief Guide to Gryphon’s Risk and Benefit Analysis of Gain of Function Research The U.S. Government (USG), as part of its continued focus on biosafety and biosecurity, has…

…center, imaging and phenotyping facilities, preclinical testing programs, Good Manufacturing Practices (GMP) facilities in the pharmacy and for Positron Emission Tomography (PET) ligands, and an animal research program. These facilities…

Novel and Exceptional Technology and Research Advisory Committee Draft Report of the Gene Drives in Biomedical Research Working Group JUNE 2021 N ovel and Exceptional Technology and Research Advisory Com…